Quality 5mg Pimobendan Chewable Tablets for Dogs, Pinpaw′s Best

• Customization: Available
• Varieties: General Disease Prevention Medicine
• Component: Pimobendan
• Model NO.: 5mg Pimobendan Chewable Tablets for Dogs
• Type: The First Class
• Pharmacodynamic Influential Factors: Incompatibility
• Storage Method: Prevent High or LowTemperature
• Veterinary Reg. No.: 180477183
• Transport Package: Bottled
• Specification: 5mg/tablet
• Trademark: pinpaw
• Origin: Changsha
• Production Capacity: 50000 Boxes Per Day

Product Description

Product Description
GENERIC NAME:
Pimobendan Chewable Tablet
MAIN COMPONENT:
Pimobendan
DESCRIPTION:
Experience the excellence of our product: a light brown, scrumptious beef-flavored tablet designed for easy dosage with score lines on both sides.
PHARMACOLOGICAL EFFECTS:
Pharmacodynamics: Embrace the power of Pimobendan, a distinguished non-glycoside cardiotonic wonder. As a benzimidazole pyridazinone derivative, it provides an uplifting positive inotropic effect. By enhancing the heart muscle's calcium sensitivity and curbing phosphodiesterase (Type III) activity, Pimobendan delivers remarkable vasodilating prowess. When combined with efficacious diuretics like furosemide, it profoundly enriches life quality and extends life expectancy in dogs battling dilated cardiomyopathy or heart valve insufficiency. For large breed dogs facing preclinical dilated cardiomyopathy, Pimobendan delays the onset of heart failure and significantly prolongs survival.
Witness the reduction of heart size in preclinical myxomatous mitral valve disease treatment with Pimobendan. This acclaimed medication extends the onset of heart failure or cardiac death in dogs by about 15 months, significantly minimizes heart volume, and enhances overall survival by approximately 170 days.
Pharmacokinetics: Once administered, Pimobendan transforms through oxidative demethylation into an active metabolite before conjugation with sulfate or glucuronide. This process ensures efficient excretion predominantly through feces. With greater than 90% protein binding in dog plasma, Pimobendan and its active metabolite establish a robust therapeutic presence.
A meticulous bioequivalence study validates our product against the esteemed reference listed drug (RLD), Pimobendan Chewable Tablet (Vetmedin^®), affirming that our product matches the RLD in bioequivalency.
INDICATIONS:
Our product is expertly formulated for dogs facing congestive cardiac failure due to heart valve insufficiencies (mitral/tricuspid regurgitation) or dilated cardiomyopathy. It serves large-breed canines with preclinical dilated cardiomyopathy, characterized by echocardiographically confirmed enlarged left ventricular diameters. Additionally, it treats preclinical myxomatous mitral valve disease, evidenced by an increased heart size and systolic mitral murmur, to delay and manage the clinical progression of CCF.
DOSAGE AND ADMINISTRATION:
For optimal results, administer an oral dose of 0.25 mg/kg of Pimobendan for your dog, twice daily, ensuring a steady and effective treatment regimen.
ADVERSE REACTIONS:
1. In certain rare instances, a minor increase in heart rate, known as a positively chronotropic effect, and occasional vomiting may be observed in a select few dogs. Fortunately, these conditions are dose-dependent and can often resolve naturally with a reduced dosage. Additionally, a scarce number of dogs may experience temporary diarrhea, diminished appetite, or lethargy.
2. While the connection to pimobendan remains unconfirmed, a very limited number of dogs might show signs affecting primary haemostasis, such as mucosal or subcutaneous hemorrhage, during treatment. Remarkably, these symptoms may resolve independently once the treatment is halted.
3. In exceptionally uncommon circumstances, dogs with mitral valve disease receiving pimobendan might experience an increase in mitral regurgitation.
PRECAUTIONS:
1. This product is unsuitable for use in cases of hypertrophic cardiomyopathies or conditions where enhancing cardiac output is unattainable due to functional or anatomical factors, such as aortic stenosis. Given that the product is mainly metabolized through the liver, it is contraindicated in dogs suffering from severe liver insufficiency.
2. The efficacy of this product remains untested in Dobermans with asymptomatic dilated cardiomyopathy (DCM) who also exhibit atrial fibrillation or sustained ventricular tachycardia.
3. The product has not undergone testing in scenarios involving asymptomatic myxomatous mitral valve disease in dogs exhibiting significant supraventricular or ventricular tachyarrhythmia.
4. Animal studies involving rats and rabbits have not indicated any teratogenic or foetotoxic outcomes from the drug. However, these studies have revealed maternotoxic and embryotoxic effects at elevated doses and confirmed that the drug is secreted in milk. The safety of this product for pregnant or nursing dogs is yet to be evaluated. It should only be administered following a thorough benefit/risk assessment by a qualified veterinarian.
5. It is imperative to regularly monitor blood glucose levels in dogs already diagnosed with diabetes mellitus during the course of treatment.
6. In the "preclinical stage" of dilated cardiomyopathy, characterized by being asymptomatic but with increased left ventricular dimensions, a thorough cardiac examination is essential, utilizing echocardiography and ambulatory ECG monitoring.
7. For preclinical myxomatous mitral valve disease (stage B2, as per ACVIM guidelines: asymptomatic with a mitral murmur of ≥3/6 and cardiomegaly due to myxomatous mitral valve disease), a diagnosis requires a detailed cardiac examination, including echocardiography and radiographic analysis.
8. It is recommended to continuously monitor cardiac function and morphology in animals undergoing treatment with pimobendan.
9. Pharmacological investigations have demonstrated no interaction between pimobendan and the cardiac glycoside ouabain. However, the pimobendan-induced enhancement of cardiac contractility is diminished when calcium channel blockers (like verapamil and diltiazem) and ß-antagonists are present.
10. Avoid exceeding the prescribed dosage. An overdose may trigger a positive chronotropic effect or induce vomiting. In such cases, reduce the dosage and commence appropriate symptomatic treatment.
11. During studies of prolonged exposure (6 months) in healthy Beagle dogs at 3 and 5 times the advised dose, some dogs exhibited mitral valve thickening and left ventricular hypertrophy. These phenomena are attributed to pharmacodynamic effects.
12. Ensure this product remains out of children's reach.
13. Always wash your hands thoroughly after handling the product.
14. Should any unfortunate incident of accidental ingestion occur, it is imperative to promptly seek medical advice and present the product label or package insert to the attending physician. This is crucial as accidental ingestion, particularly by a child, can result in symptoms such as increased heart rate, orthostatic hypotension, facial flushing, and headaches.
15. It is essential that any leftover veterinary medicinal product, or waste material derived from it, be disposed of following local regulations. To ensure proper disposal, consult with local veterinarians. This ensures that disposal methods align with stringent environmental protection standards, maintaining ecological integrity while adhering to legal requirements.